67 related articles for article (PubMed ID: 20827732)
1. Evaluation of changes in serum protein profiles during neoadjuvant chemotherapy in HER2-positive breast cancer using an LC-MALDI-TOF/MS procedure.
Mazouni C; Baggerly K; Hawke D; Tsavachidis S; André F; Buzdar AU; Martin PM; Kobayashi R; Pusztai L
Proteomics; 2010 Oct; 10(19):3525-32. PubMed ID: 20827732
[TBL] [Abstract][Full Text] [Related]
2. Identification of serum protein markers for breast cancer relapse with SELDI-TOF MS.
Lei L; Wang XJ; Zheng ZG; Huang J; Cao WM; Chen ZH; Shao XY; Cai JF; Ye WW; Lu HY
Anat Rec (Hoboken); 2011 Jun; 294(6):941-4. PubMed ID: 21548109
[TBL] [Abstract][Full Text] [Related]
3. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A
Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
[TBL] [Abstract][Full Text] [Related]
4. Reproducibility of serum protein profiling by systematic assessment using solid-phase extraction and matrix-assisted laser desorption/ionization mass spectrometry.
Callesen AK; Christensen Rd; Madsen JS; Vach W; Zapico E; Cold S; Jørgensen PE; Mogensen O; Kruse TA; Jensen ON
Rapid Commun Mass Spectrom; 2008; 22(3):291-300. PubMed ID: 18181248
[TBL] [Abstract][Full Text] [Related]
5. Predictive value of relative changes in serum total sialic acid level for response to neoadjuvant chemotherapy in patients with locally advanced breast carcinoma.
Celen O; Yildirim E; Ozen N; Sonmez C
Neoplasma; 2006; 53(4):347-51. PubMed ID: 16830065
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant chemotherapy of breast cancer: tumor markers as predictors of pathologic response, recurrence, and survival.
Precht LM; Lowe KA; Atwood M; Beatty JD
Breast J; 2010; 16(4):362-8. PubMed ID: 20443786
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Ki-67 proliferation and apoptotic index before, during and after neoadjuvant chemotherapy for primary breast cancer.
Burcombe R; Wilson GD; Dowsett M; Khan I; Richman PI; Daley F; Detre S; Makris A
Breast Cancer Res; 2006; 8(3):R31. PubMed ID: 16790076
[TBL] [Abstract][Full Text] [Related]
8. Proteomic tracking of serum protein isoforms as screening biomarkers of ovarian cancer.
Ahmed N; Oliva KT; Barker G; Hoffmann P; Reeve S; Smith IA; Quinn MA; Rice GE
Proteomics; 2005 Nov; 5(17):4625-36. PubMed ID: 16220531
[TBL] [Abstract][Full Text] [Related]
9. Breast cancer and neoadjuvant therapy: any predictive marker?
Vyzula R; Dusek L; Zaloudík J; Demlová R; Klimes D; Selvekerová S
Neoplasma; 2004; 51(6):471-80. PubMed ID: 15640958
[TBL] [Abstract][Full Text] [Related]
10. alphaB-crystallin is a novel predictor of resistance to neoadjuvant chemotherapy in breast cancer.
Ivanov O; Chen F; Wiley EL; Keswani A; Diaz LK; Memmel HC; Rademaker A; Gradishar WJ; Morrow M; Khan SA; Cryns VL
Breast Cancer Res Treat; 2008 Oct; 111(3):411-7. PubMed ID: 17968656
[TBL] [Abstract][Full Text] [Related]
11. Biomarker discovery for ovarian cancer using SELDI-TOF-MS.
Zhang H; Kong B; Qu X; Jia L; Deng B; Yang Q
Gynecol Oncol; 2006 Jul; 102(1):61-6. PubMed ID: 16403569
[TBL] [Abstract][Full Text] [Related]
12. Different criteria for HER2 positivity by IHC can be applied in post-chemotherapy specimens in determining HER2 as a prognosticator in locally advanced breast cancer.
Moon YW; Jeung HC; Rha SY; Choi YH; Yang WI; Chung HC
Breast Cancer Res Treat; 2007 Jul; 104(1):31-7. PubMed ID: 17587181
[TBL] [Abstract][Full Text] [Related]
13. Predictive biological markers for response of invasive breast cancer to anthracycline/cyclophosphamide-based primary (radio-)chemotherapy.
Prisack HB; Karreman C; Modlich O; Audretsch W; Danae M; Rezai M; Bojar H
Anticancer Res; 2005; 25(6C):4615-21. PubMed ID: 16334152
[TBL] [Abstract][Full Text] [Related]
14. Elucidation of potential bortezomib response markers in mutliple myeloma patients.
Hsieh FY; Tengstrand E; Pekol TM; Guerciolini R; Miwa G
J Pharm Biomed Anal; 2009 Jan; 49(1):115-22. PubMed ID: 19062221
[TBL] [Abstract][Full Text] [Related]
15. Accurately assessing her-2/neu status in needle core biopsies of breast cancer patients in the era of neoadjuvant therapy: emerging questions and considerations addressed.
D'Alfonso T; Liu YF; Monni S; Rosen PP; Shin SJ
Am J Surg Pathol; 2010 Apr; 34(4):575-81. PubMed ID: 20216378
[TBL] [Abstract][Full Text] [Related]
16. Identification of potential markers for the detection of pancreatic cancer through comparative serum protein expression profiling.
Ehmann M; Felix K; Hartmann D; Schnölzer M; Nees M; Vorderwülbecke S; Bogumil R; Büchler MW; Friess H
Pancreas; 2007 Mar; 34(2):205-14. PubMed ID: 17312459
[TBL] [Abstract][Full Text] [Related]
17. A serum proteomic pattern for the detection of colorectal adenocarcinoma using surface enhanced laser desorption and ionization mass spectrometry.
Liu XP; Shen J; Li ZF; Yan L; Gu J
Cancer Invest; 2006 Dec; 24(8):747-53. PubMed ID: 17162557
[TBL] [Abstract][Full Text] [Related]
18. Characterization of proteins in human pancreatic cancer serum using differential gel electrophoresis and tandem mass spectrometry.
Yu KH; Rustgi AK; Blair IA
J Proteome Res; 2005; 4(5):1742-51. PubMed ID: 16212428
[TBL] [Abstract][Full Text] [Related]
19. HER2 and topoisomerase IIalpha: possible predictors of response to neoadjuvant chemotherapy for breast cancer patients.
Zhu L; Li YF; Chen WG; He JR; Peng CH; Zhu ZG; Li HW
Chin Med J (Engl); 2008 Oct; 121(20):1965-8. PubMed ID: 19080257
[TBL] [Abstract][Full Text] [Related]
20. Optimization of analytical and pre-analytical conditions for MALDI-TOF-MS human urine protein profiles.
Calvano CD; Aresta A; Iacovone M; De Benedetto GE; Zambonin CG; Battaglia M; Ditonno P; Rutigliano M; Bettocchi C
J Pharm Biomed Anal; 2010 Mar; 51(4):907-14. PubMed ID: 19939598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
